Outcomes of adjunctive therapies post hedgehog inhibitors in the management of locally advanced basal cell carcinoma: A systematic review and pooled analysis-Reference-Cited by-同舟云学术

Outcomes of adjunctive therapies post hedgehog inhibitors in the management of locally advanced basal cell carcinoma: A systematic review and pooled analysis

Published:2021-10-28 Issue:6 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Patel Arsh¹,Kim Jane S.²,Liss Jason²,Howard Lauren³,Jung Sin‐Ho³,Kheterpal Meenal¹

Affiliation:

1. Department of Dermatology Duke University School of Medicine Durham North Carolina USA

2. Department of Ophthalmology Duke University School of Medicine Durham North Carolina USA

3. Department of Biostatistics and Bioinformatics Duke University School of Medicine Durham North Carolina USA

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15172

Reference53 articles.

1. Vismodegib

2. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study

3. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

4. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

5. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma;Cancer Treatment and Research Communications;2024

2. Complete pathologic clearance with vismodegib in advanced basal cell carcinoma of the scalp with cranial invasion;JPRAS Open;2022-12

3. Sonidegib treatment in patients with locally advanced basal cell carcinoma;Dermatologic Therapy;2022-02-14